A Therapy's Effect on Reduction of Exacerbations is the Attribute That Most Influences Physicians' Prescribing Decisions, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Novartis/Schering-Plough's indacaterol/mometasone will replace AstraZeneca's Symbicort as Decision Resources' proprietary clinical gold standard by 2012 for the treatment of asthma due to its once-daily dosing competitive advantage. In fact, because none of the therapies projected to launch within the next ten years are expected to offer advantages in efficacy over currently marketed long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, Decision Resources' gold standard will be determined by incremental advantages in delivery, such as less-frequent daily dosing and a faster onset of action.
"Physicians we interviewed report that once-daily dosing has the potential to increase patient compliance. Patient compliance is important because asthma is a chronic disease that requires consistent administration of anti-inflammatory drugs to reduce disease severity and limit costly emergency healthcare," said Martin Quinn, analyst at Decision Resources.
The new report entitled Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves from Existing Agents in the Class also finds that a therapy's effect on reducing exacerbations is the attribute that most influences physicians' prescribing decisions in asthma. Based on U.S. and European surveyed physicians, current and emerging therapies have no advantage over sales-leading GlaxoSmithKline's Advair/Seretide/Adoair on this attribute.
About the Report
Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved